

# Extended-Spectrum Beta-Lactamases (ESBLs) and the detection methods

by

**Dr. Kais Kassim Ghaima**


**Microbial Genetics**

معهد الهندسة الوراثية والتقنيات الاحيائية - جامعة بغداد

# Why ESBL detection is important?

- **ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world.**
- **ESBL pose challenging infection control issues.**
- **ESBLs are clinically significant and indicate the appropriate antibacterial agents.**
- **Improve clinical outcome**
- **Inappropriate treatment leads to poor outcome**
- **Each 1 hour delay increases mortality by 7.6%.**
- **Identify emerging resistance problems**

- **$\beta$ -lactam antibiotics**
- – **Penicillin**
- – **Cephalosporin**
- – **Monobactam**
- – **Carbapenem**



# Penicillins

- **$\beta$  Lactamase-sensitive Penicillins**
  - Penicillin G/V
  - Ampicillin
  - Amoxicillin
- **Anti-staphylococcal Penicillins**
  - Oxacillin
  - Nafcillin
  - Dicloxacillin
- **Anti-pseudomonal Penicillins**
  - Ticarcillin
  - Piperacillin

# Cephalosporins

- **First generation** (Moderate spectrum)
  - Cefazolin · Cephalexin
- **Second generation** (Moderate spectrum)
  - Cefaclor · Cefuroxime
- **Third generation** (Broad spectrum)
  - Cefixime · Cefotaxime · Ceftriaxone  
Ceftazidime
- **Fourth generation** (Broad spectrum)
  - Cefipime

# Carbapenem (Imipenem & Meropenem)

## ❖ **Mechanism of action:**



- Same as penicillin and cephalosporin.
- Broad spectrum, resistant to B lactamase.
- Imipenem is quickly degraded by renal dehydropeptidase . So it's always administered with cilastatin (inhibitor of renal dehydropeptidase) to prevent the degradation of imipenem.

# Monobactam (Aztreonam)


## ❖ Mechanism of action:

- Prevents peptidoglycan cross linking like penicillins & cephalosporins.
- Resistant to B-lactamase.
- Synergistic with aminoglycosides.
- NO cross-allergenicity with penicillins.

Penicillin



Cephalosporin



inactive metabolites

- **$\beta$  lactamases**
- **Beta lactamases are enzymes produced by some bacteria that hydrolyze beta lactam antibiotics.**
- **Penicillinases, Cephalosporinases**
- **Extended spectrum  $\beta$ -lactamases (ESBL)**
- **Metallo  $\beta$  lactamases**
- **Amp C**
- **Carbapenemase**



# TYPES OF B-LACTAMASES

- **$\beta$ -lactamases**

- Penicillinase: gene *blaZ*, inducible, on transposon (can move between chromosome and plasmid).

- **Broad spectrum  $\beta$ -lactamases**

- (plasmid encoded)
- TEM
- SHV
- OXA (mainly in pseudomonas)

- **ESBLs**

- TEM related
- SHV related
- OXA related
- CTX-M
- Other


- ***ampC*  $\beta$ -lactamases**

- Resistant to  $\beta$ -lactamase inhibitors
- chromosomal

- **Carbapenemases**

- Metallo-  $\beta$ -lactamases
- Serine carbapenemases

## Ambler molecular classification




## Bush-Jacoby-Medeiros functional classification

- Group 1: cephalosporinases (Ambler Class C)
- Group 2: serine- $\beta$ -lactamase (Ambler Class A and D)
- Group 3: metallo- $\beta$ -lactamase (Ambler Class B)

- **Definition**
- **ESBLs are enzymes**
  - – hydrolyzing most penicillins and cephalosporins,
  - and monobactam (aztreonam).
  - – but not cephamycins and carbapenems
  - – Susceptible to  $\beta$ -lactamase inhibitors
  - (**clavulanate, sulbactam and tazobactam**)

### Genes

*bla*-SHV  
*bla*TEM  
*bla*CTX-M  
*bla*OXA  
*bla*PER  
*bla*VEB



# ESBL

- Confer resistance to 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> cephalosporins.
  - Most are susceptible to  $\beta$ -lactamase inhibitors
  - Most are susceptible to 4<sup>th</sup> cephalosporins
  - All are susceptible to carbapenems
- Diversity of ESBL
  - SHV (widespread)
  - TEM (>100 types)
  - OXA
    - Predominantly in Pseudomonas
    - less susceptible to  $\beta$ -lactamase inhibitors
  - CTX-M
    - Probably independent evolution
    - Highly resistant to 3<sup>rd</sup> generation cephalosporins
    - initially in South America, Far East & Eastern Europe
    - Probably most frequent worldwide
    - Clonal spread has been documented

# BETA-LACTAMASE INHIBITORS

- Resemble  $\beta$ -lactam antibiotic structure Bind to  $\beta$ -lactamase and protect the antibiotic from destruction
- Most successful when they bind the  $\beta$ -lactamase irreversibly
- Three important in medicine
- **Clavulanic acid**
- **Sulbactam**
- **Tazobactam**

## Drug Name

Augmentin XR (Pro)

Generic name: amoxicillin / clavulanate

Unasyn (Pro)

Generic name: ampicillin / sulbactam


Zosyn (Pro)

Generic name: piperacillin / tazobactam

# Common ESBL producers

Type	Major sources
TEM, SHV	<i>E. coli, K. pneumoniae</i>
Cefotaxime hydrolyzing (CTX-M)	<i>S. Typhimurium, E. coli, K. pneumoniae</i>
Oxacillin hydrolyzing (OXA)	<i>P. aeruginosa</i>
PER-1	<i>P. aeruginosa, A. baumannii, S. Typhimurium</i>
PER-2	<i>S. Typhimurium</i>
VEB-1	<i>E. coli, P. aeruginosa</i>

- **Mechanisms of resistance**
- The majority of ESBLs are acquired enzymes ( Plasmids).
- **Different resistance phenotypes to:**
  - Different expression levels
  - Different biochemical characteristics such as
  - Activity against specific  $\beta$ -lactams
  - Co-presence of other resistance mechanisms (other  $\beta$ -lactamases, efflux, altered permeability).



## CHOICE OF INDICATOR CEPHALOSPORIN

- **TEM & SHV** – obvious resistance to ceftazidime, variable to cefotaxime
- **CTX-M** – obvious resistance to cefotaxime, variable to ceftazidime
- **All ESBLs** – obvious resistance to
- Cefpodoxime.
- Cefuroxime, cephalixin and cephradine are **unreliable** indicators



- **Risk factors**

- Many ESBL producers are multi-resistant to non- $\beta$ -lactam antibiotics such as quinolones, aminoglycosides and trimethoprim, narrowing treatment options.
- ESBLs destroy cephalosporins, main hospital antibiotics, given as first-line agents to many severely-ill patients, including community-acquired pneumonias and bacteraemias.
- Critically ill patients, Immunosuppression and ICU patients.
- Invasive procedures: intubation, mechanical ventilation, catheter
- Family member with multidrug-resistant pathogens
- High frequency of antibiotic resistance in the community or in the specific hospital unit.

# Laboratory Detection of ESBL

Phenotypic  
Methods

Genotypic  
Methods

Screening  
methods

Confirmatory  
Methods

# Screening methods





## Screening for ESBL producers.



- (i) Disk diffusion methods.
- Isolates with a cefpodoxime (10- $\mu$ g) zone diameter of  $\leq 17$  mm should undergo phenotypic confirmatory tests for ESBL production.
- (ii) Screening by dilution antimicrobial susceptibility tests.
- Useful screening test for cefpodoxime is to use a cefpodoxime MIC of  $\geq 8$   $\mu$ g/ml, as a trigger to perform phenotypic confirmatory tests for ESBL production

- **Confirmatory methods**

- 1- Combination disk

- – Uses 2 disks of 3rd cephalosporin alone and
- combined with clavulanic acid
- – An increase of  $\geq 5$  mm in zone inhibition with use
- of the combination disk.





**Klebsiella pneumoniae  
ATCC 700603**



**CAZ  
30**



**CAZ/Clav  
30/10**




**CTX  
30**




**CTX/Clav  
30/10**

# Phenotypic conformation

- 2- Double disk approximation or double disk synergy
- – Disk of 3rd cephalosporin placed 30 mm from amoxicillin clavulanic acid
- – Result: Enhanced inhibition (A keyhole or ghost zone).





Ceftriaxone



Cefotaxime

Amox-clav

Ceftazidime

Azteonam





- **Phenotypic conformation**
- **3- E-test (MIC ESBL strips)**
- Two-sided strip containing cephalosporin on one side and cephalosporin -clavulanic acid on the other
- MIC ratio  $\geq 8$
- $>8$  fold reduction in MIC in presence of CA= ESBL
- or Phantom zone (deformed ellipse)




MIC = 16

**Ceftaz**

64fold

MIC = 0.25

**Ceftaz/CA**



**Cefotaxime**

**Cefotaxime  
+  
clavulanate**



- **Phenotypic conformation**

- 4- Broth Microdilution

- MIC of 3rd cephalosporin alone and combined with clavulanic acid
- >3-two fold serial dilution decrease in MIC of either cephalosporin in the presence of clavulanic acid compared to its MIC when tested alone.
- **Ceftazidim MIC =8 µg/mL**
- **Ceftazidime + Clavulanate= 1 µg/mL**
- **Or MIC ratio≥8**

- 5- MIC broth dilution


- **MIC of 3rd cephalosporin** alone and combined with clavulanic acid
- A decrease in the MIC of the combination of > 3-two fold dilutions



# Other confirmatory methods

## Brilliance ESBL agar

- identification of ESBL-producing *E. coli*, *Klebsiella*, *Enterobacter*, *Serratia* and *Citrobacter* group, directly from clinical samples.
- two chromogens that specifically target enzymes → green and blue colonies
- Negative → pink.
- *Proteus*, *Morganella* and *Providencia* → tan-coloured colonies with a brown halo



**Selective agar with multiple antibiotics including cefpodoxime • Rapid detection of common ESBL+ enterobacteria within 18-24h of specimen.**

- **Other confirmatory methods**
- **6- Automated instruments**
- Measure MICs and compare the growth of bacteria in presence of cephalosporin vs. cephalosporin - clavulanic acid

Vitek ESBL  
confirmatory test



Phoenix ESBL test  
(BD)




Microscan  
ESBL Panel

# Evaluation of the automated detection

- The **BD Phoenix ESBL screening test**, included in both panels, utilizes the growth response to selected cephalosporins (cefotaxime, ceftazidime, cefpodoxime, and ceftriaxone), with or without clavulanic acid, to detect the production of ESBLs. The results are analyzed with the integrated **BDXpert system**.
- **For the evaluation of the Vitek 2 system**, the ESBL confirmatory test is incorporated on cards AST-N041 and AST-N062. This ESBL screening test utilizes the growth response to ceftazidime, cefepime, and cefotaxime in combination with or without clavulanic acid on both cards. All results were interpreted by using the **Advanced Expert System (AES)**.




- **Genotypic confirmation**
- **Molecular detection (ESBL genes) in ESBL producing bacteria**
  - – PCR
  - – RFLP
  - – Gene sequencing
  - – DNA microarray-based method
- Targets specific nucleotide sequences to detect different variants of TEM and SHV genes.
- In the clinical diagnostic laboratory
  - – Directly from specimens
  - – Need to target key species
  - – Format must be simple, rapid and cost-effective
  - – Problems with genes in commensals.



**Figure (4-7):** Agarose gel electrophoresis for detection the resistance genes *blaSHV*, *blaTEM*, and *blaCTX-M*- by multiplex PCR. Lane M: 100bp DNA ladder; lanes 2-13: *K. pneumoniae* 40-52 isolates; lane 1: Negative control. (70V for 2hr).

# Alignment of *bla*SHV sequences of *Klebsiella pneumoniae* isolates





# BACTERIA NOT TO TEST FOR ESBL'S

- *Acinetobacter*
  - Acinetobacter often S to clavulanate alone
- *S. maltophilia*
  - You get +ve results via inhibition of L-2 chromosomal  $\beta$ -lactamase, which is ubiquitous in the species

